The U.S. military says it is months away from launching clinical trials of a pill designed to block or reduce many degenerative effects of agingan oral treatment that a leading researcher in the field says is better than nothing while questioning how effective it will ultimately prove.
U.S. Special Operations Command (SOCOM)which develops and employs Special Operations Forces worldwide to advance U.S. policies and objectiveshas completed preclinical safety and dosing studies in anticipation of follow-on performance testing of a first-in-class nicotinamide adenine dinucleotide, oxidized state (NAD+) enhancer, a small molecule drug being developed by Metro International Biotech (MetroBiotech), Navy Cmdr. Timothy A. Hawkins, a spokesperson for SOCOM, told GEN.
SOCOM and MetroBiotech are set to start clinical trials during the 2022 federal fiscal year, which starts October 1.
If the preclinical studies and clinical trials bear out, the resulting benefits include improved human performance, such as increased endurance and faster recovery from injury, Hawkins said.
This effort in particular is about enhancing the mission readiness of our forces by improving performance characteristics that typically decline with age, Hawkins explained. These efforts are not about creating physical traits that dont already exist naturally.
The SOCOM testing is among studies being carried out to assess MetroBiotechs lead candidate, David J. Livingston, PhD, MetroBiotechs president and CSO, told GEN.
I can confirm that we and our clinical partners have completed multiple Phase I human safety trials of a lead molecule, Livingston said. Metrohas also initiated exploratory Phase II studies in several areas of therapeutic application, including the treatment of rare diseases, diseases of aging, and incollaboration with SOCOM, studies on the effects of our compounds on muscle energetics and human performance.
Livingston said MetroBiotech wont discuss details of its clinical trials in advance offuture postings on ClinicalTrials.govor joint publications of clinical data.
SOCOM has spent $2.8 million on its anti-aging effort since it began in 2018, Hawkins said.
Lisa R. Sanders, director of science and technology for Special Operations Forces, Acquisition, Technology, & Logistics, said during a virtual conference last month that SOCOM was able to fund its anti-aging testing through Other Transaction Authority (OTA) funds and Middle Tier Acquisition authority, created in 2015 to enable rapid acquisitions designed to deliver capabilities within 25 years.
This small molecule has the potential, if it is successful, to truly delay aging [and] truly prevent onset of injury, which is just amazingly game-changing, Sanders said, addressing Assisting the Modern Warfighter, a featured session held as part of the Defense One Defense Tech Summit, held June 2125.
Weve stayed out of long-term genetic engineeringthat makes people very, very uncomfortablebut theres a huge commercial marketplace for things that can avoid injury, that can slow down aging, that can improve sleep, Sanders added.
That marketplace is set to grow 55% over the next five years, according to a market study issued in January by 360 Market Updates, from $84.6 billion this year to $130.87 billion by 2026a compound annual growth rate of 7.5%.
Can MetroBiotechs treatment be the one that can tap into that potentially lucrative anti-aging marketplace?
This is better than nothing, but not much better, cautioned Aubrey D.N.J. de Grey, PhD, a biomedical gerontologist who is CSO and co-founder of SENS Research Foundation. De Grey is also editor-in-chief of Rejuvenation Research, a peer-reviewed journal published by GEN publisher Mary Ann Liebert, Inc., publishers.
Based in Mountain View, CA, SENS Research Foundation aims to prevent and reverse age-related ill-health by applying principles of regenerative medicine to repair the damage of agingat the level where it occurs. The foundation focuses on rejuvenation biotechnologies designed to restore the normal functioning of the bodys cells and essential biomolecules, returning aging tissues to health and bringing youthful vigor back to the human body.
According to de Grey, SENS approach to anti-aging contrasts with MetroBiotechs, which he characterized as reflective of a consensus view within gerontology toward simply reducing the rate of cellular damage from aging.
Unfortunately the field of gerontology went about it in another wrong way, which was to try to, in effect, clean up metabolism, to slow down the rate at which metabolism generates damage and thereby to postpone the age at which damage reaches this pathogenic threshold. That has been basically unsuccessful, de Grey said. The pill that MetroBiotech is looking at is probably going to fail, for that reason.
Not so, insists MetroBiotech.
Our companys strategy is to design small molecule therapeutics that leverage our scientists detailed understanding of the biochemistry and genetics of human pathways of aging and stress response, Livingston said. Based on discoveries in these exciting areas of biology, Metro has created a library of novel NAD enhancers as therapeutics for the treatment of human disease and preservation of muscle and cognitive performance.
Privately-owned MetroBiotech, based in Worcester, MA, states on its website that it has established the most comprehensive portfolio of proprietary NAD+ precursors in the world. The company reasons that increasing NAD+ to preserve health and normal metabolism has broad pharmaceutical potential since levels of NAD+ have been shown to decline as people age. Reduced levels of NAD+ are linked to aging and numerous diseases, including mitochondrial dysfunction, inflammation, and a variety of associated diseases.
NAD+ plays a key role in the function of all living cells,as a cofactor required for the enzymatic processes that generate energy within the cell through the adenosine triphosphate (ATP) cycleboth in traditional oxidoreductase reactions and as a signaling molecule for reactions catalyzed by sirtuins, which regulate cellular health, and poly-ADP ribose polymerases (PARPS), proteins that help cells repair themselves.
MetroBiotechs lead pipeline candidate, MIB-626, is one of over 100 novel NAD+ enhancers the company says it has designed, synthesized, and screened for optimal therapeutic properties. MetroBiotech says its efforts have resulted in robust preclinical data that support the broad therapeutic potential of modulating NAD+.
Most recently, in a study published last year in the journal Experimental Neurology, researchers at Medical University of South Carolina and Ecole Polytechnique Fdrale de Lausanne (EPFL) in Switzerland studies two approaches to increasing NAD+availability in mouse models of amyotrophic lateral sclerosis (ALS): Ablation of a NAD+-consuming enzyme (CD38), and supplementation with a bioavailable NAD+precursor, nicotinamide riboside or NR.
While the ablation approach showed no effect on the survival of the mouse models, adding NR delayed motor neuron degeneration, decreased markers of neuroinflammation in the spinal cord, appeared to modify muscle metabolism and modestly increased the survival of the hybrid superoxide dismutase 1 G93A (hSOD1G93A) mouse model of ALS.
The results indicate that the approach used to enhance NAD+levels critically defines the biological outcome in ALS models, suggesting that boosting NAD+levels with the use of bioavailable precursors would be the preferred therapeutic strategy for ALS, researchers concluded in the study, whose corresponding author Marcelo R. Vargas, PhD, is now at University of Wisconsin-Madison.
While acknowledging that an oral treatment to reverse aging would be much easier for patients than a surgical approach, de Grey of SENS added; The way I look at it is, first of all get something that works, even if its really nasty in terms of needing surgery, and then you can refine it and make it injectable and maybe even oral.
He cited growing researcher interest in an anti-aging application for one already-marketed drug long in use by patients. The type 2 diabetes treatment Metformin is set to be the subject of the proposed Targeting Aging with Metformin (TAME) Trial. TAME, to be managed by the American Federation for Aging Research, will be a series of nationwide, six-year clinical trials at 14 top-tier research institutions across the United States that are designed to engage over 3,000 individuals between the ages of 6579.
Another potential anti-aging treatment already under clinical study is rapamycin, a natural anti-fungal antibiotic that has shown antitumor and immunosuppressive activity. The University of California, Los Angeles, partnered with AgelessRx last year to launch the Phase II Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study (PEARL) trial (NCT04488601), designed to evaluate Rapamycin in an estimated 1,000 older adults.
The researchers aim to establish a long-term safety profile, determine the long-term efficacy of Rapamycin in reducing clinical aging measures, and biochemical and physiological endpoints associated with declining health and aging in healthy older adults, according to the trials ClinicalTrials.gov page.
MetroBiotech has disclosed one clinical trial for its lead NAD+ candidate MIB-626 on ClinicalTrials.gov. The Phase II trial (NCT04817111) does not involve SOCOM, but is designed instead to assess MIB-626 in up to 10 adults with Friedreichs Ataxia (FA) without overt heart failure and with a left ventricular ejection fraction 40%.
A key secondary objective is to test the effects of MIB-626 on cardiac and skeletal muscle bioenergetics, according to MetroBiotech.
The trials estimated primary completion date is April 10, 2022.
Link:
US Special Operations Command to Test Anti-Aging Pill - Genetic Engineering & Biotechnology News
- Viewpoint: Anti-GMO arguments seem silly after 28 years of false narratives about health harms and and genetic ... - Genetic Literacy Project - March 29th, 2024 [March 29th, 2024]
- Viewpoint: Here's how genetically engineered fruits and vegetables will soon emerge as a grocery store 'selling point ... - Genetic Literacy Project - March 29th, 2024 [March 29th, 2024]
- CRISPR Investments: What We Heard at World Agri-Tech - Seed World - March 29th, 2024 [March 29th, 2024]
- When SpaceX's Starship is ready to settle Mars, will we be? (op-ed) - Space.com - September 17th, 2023 [September 17th, 2023]
- Genome-wide promoter responses to CRISPR perturbations of ... - Nature.com - September 17th, 2023 [September 17th, 2023]
- Expanding the toolbox for RNA editing | ASU News - ASU News Now - September 17th, 2023 [September 17th, 2023]
- Electrical Engineer Named MIT Technology Review Innovator Under ... - University of California San Diego - September 17th, 2023 [September 17th, 2023]
- Can we rely on our 'moral force-field' to stop cloning going too far? - The National - September 17th, 2023 [September 17th, 2023]
- Otsuka Collaborates with ShapeTX for Development of AAV Gene ... - Pharmaceutical Technology Magazine - September 17th, 2023 [September 17th, 2023]
- Cancer discovery earns U of A grad the Breakthrough Prize - University of Alberta - September 17th, 2023 [September 17th, 2023]
- The Brave New World of synthetic humans | Gne Taylor - IAI - September 17th, 2023 [September 17th, 2023]
- Targeting Tumors with Photosynthetic Bacteria - Optics & Photonics News - September 17th, 2023 [September 17th, 2023]
- Artificial Photosynthesis Breakthrough Researchers Produce ... - SciTechDaily - September 17th, 2023 [September 17th, 2023]
- BASF patent on watermelons upheld: European Patent Office rejects ... - Bio Eco Actual - September 17th, 2023 [September 17th, 2023]
- Space Industry Is Growing Faster Than Its Workforce, Analysts Say - Slashdot - September 17th, 2023 [September 17th, 2023]
- New 'Inverse Vaccine' Shows Potential to Treat MS and Other ... - Slashdot - September 17th, 2023 [September 17th, 2023]
- Gene therapy: Donor DNA may protect babies from certain disorders - Medical News Today - May 18th, 2023 [May 18th, 2023]
- Viewpoint: Grim consequences of Greenpeace's war on ... - Genetic Literacy Project - May 18th, 2023 [May 18th, 2023]
- Predicting Diabetic Kidney Disease with the Use of a Novel Algorithm - Genetic Engineering & Biotechnology News - May 18th, 2023 [May 18th, 2023]
- Quantum biology on horizon? How futuristic physics theory could ... - Study Finds - May 18th, 2023 [May 18th, 2023]
- Scientists can collect human DNA from water, air, and basically ... - Earth.com - May 18th, 2023 [May 18th, 2023]
- The First Crispr-Edited Salad Is Here - WIRED - May 18th, 2023 [May 18th, 2023]
- Gene editing technology used to produce disease-resistant calf - Earth.com - May 18th, 2023 [May 18th, 2023]
- Neanderthals passed down their tall noses to modern humans ... - Livescience.com - May 18th, 2023 [May 18th, 2023]
- Squid Camouflage Inspires Human Invisibility: Is it Possible? - DISCOVER Magazine - May 18th, 2023 [May 18th, 2023]
- Mice Model Technologies Market Poised for 7.4% CAGR Growth, Reaching USD 3.2 Bn by 2031 | Transparency Market Research - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Google Cloud launches A.I.-powered tools to accelerate drug discovery, precision medicine - CNBC - May 18th, 2023 [May 18th, 2023]
- How Fauci, scientists with ties to Wuhan lab persuaded the ... - U.S. Right to Know - May 18th, 2023 [May 18th, 2023]
- The Daunting Task of Cutting Heavy Metals from Baby Food - Undark Magazine - May 18th, 2023 [May 18th, 2023]
- Ingestible Device Profiles and Peers into the Microbiome and ... - Genetic Engineering & Biotechnology News - May 18th, 2023 [May 18th, 2023]
- X-Men Officially Names the Best Powers Any Mutant Can Have - Screen Rant - May 18th, 2023 [May 18th, 2023]
- 10 Forgotten Marvel Comics Characters That Debuted In The '80s - Screen Rant - May 18th, 2023 [May 18th, 2023]
- 18 Human Genetic Engineering - Clemson University - April 19th, 2023 [April 19th, 2023]
- Pros and Cons of Genetic Engineering - Benefits and Risks - March 31st, 2023 [March 31st, 2023]
- What is Genetic Engineering? Types, Process & Applications - March 31st, 2023 [March 31st, 2023]
- How artificial skin is made and its uses, from treating burns to skin cancer - South China Morning Post - March 31st, 2023 [March 31st, 2023]
- Welcome to the UNC Department of Genetics | Department of Genetics - February 5th, 2023 [February 5th, 2023]
- Global Genetically Modified Crops Market Is Projected To Grow At A 6% Rate Through The Forecast Period - EIN News - February 5th, 2023 [February 5th, 2023]
- Science and History of GMOs and Other Food Modification Processes - February 2nd, 2023 [February 2nd, 2023]
- Genetics | History, Biology, Timeline, & Facts | Britannica - January 31st, 2023 [January 31st, 2023]
- Human genetics | Description, Chromosomes, & Inheritance - January 31st, 2023 [January 31st, 2023]
- Genetic testing - Mayo Clinic - January 31st, 2023 [January 31st, 2023]
- Genetic Disorders: What Are They, Types, Symptoms & Causes - January 31st, 2023 [January 31st, 2023]
- Colossal Biosciences Project to Revive the Prehistoric Woolly Mammoth Raises Staggering $60 Million Series A Funding - Nature World News - January 22nd, 2023 [January 22nd, 2023]
- 2023 is going to witness a surge in technology courses top courses that will remain in vogue - Times of India - January 22nd, 2023 [January 22nd, 2023]
- M.R.S. Rao birthday: All you need to know about the Padma Shri winning Indian scientist - Free Press Journal - January 22nd, 2023 [January 22nd, 2023]
- Russian cosmism - Wikipedia - January 8th, 2023 [January 8th, 2023]
- Postgenderism - Wikipedia - January 8th, 2023 [January 8th, 2023]
- LessWrong - Wikipedia - January 8th, 2023 [January 8th, 2023]
- Eliezer Yudkowsky - Wikipedia - January 8th, 2023 [January 8th, 2023]
- Genetic Engineering Principles of Biology - December 26th, 2022 [December 26th, 2022]
- Engineering the Perfect Baby | MIT Technology Review - December 26th, 2022 [December 26th, 2022]
- Genetic Engineering Science Projects - Science Buddies - December 21st, 2022 [December 21st, 2022]
- DSI adoption at COP15 can financially help protect biodiversity in India: Experts - The Tribune India - December 21st, 2022 [December 21st, 2022]
- Tel Aviv University researchers demonstrate success of potential one-time vaccine to treat HIV/AIDS - ETHealthWorld - December 21st, 2022 [December 21st, 2022]
- Should You Buy 22nd Century Group Inc (XXII) Stock After it Has Risen 14.29% in a Week? - InvestorsObserver - October 28th, 2022 [October 28th, 2022]
- Home :: National Institute for Biotechnology and Genetic Engineering - October 11th, 2022 [October 11th, 2022]
- A recently discovered law of physics could help predict genetic mutations - October 11th, 2022 [October 11th, 2022]
- Farmers, consumers will embrace GMOs if they understand them - The Standard - October 11th, 2022 [October 11th, 2022]
- Synthetic Biology Market is Expected to Report a CAGR of ~21% from 2021 to 2029: Industry Size, Growth & Forecast at Douglas Insights - Yahoo... - October 11th, 2022 [October 11th, 2022]
- After 45 years of science-based art, Esther Klein Gallery winds down - WHYY - October 11th, 2022 [October 11th, 2022]
- Behind this Nobel prize is a very human story: theres a bit of Neanderthal in all of us - The Guardian - October 11th, 2022 [October 11th, 2022]
- The key to tastier beer might be mutant yeastwith notes of banana - Popular Science - October 11th, 2022 [October 11th, 2022]
- Why You'll Probably Never See Cotton Candy Grape Wine - Tasting Table - October 11th, 2022 [October 11th, 2022]
- Earth materials in technology The National - The National - October 11th, 2022 [October 11th, 2022]
- CULINARY THRILL SEEKING Proceed with caution. It's hotter than blazes season. - Port Arthur News - The Port Arthur News - October 11th, 2022 [October 11th, 2022]
- Give legal rights to animals, trees and rivers, say experts - The Guardian - October 11th, 2022 [October 11th, 2022]
- How yeast DNA may help protect astronauts from cosmic radiation in space - EastMojo - October 11th, 2022 [October 11th, 2022]
- Life finds a way, but should it? The ethics of genetic engineering - The Trinitonian - October 8th, 2022 [October 8th, 2022]
- To modify or not to modify? Genetic Modification and Gene Editing - A divergence by the UK - Lexology - October 8th, 2022 [October 8th, 2022]
- Gene Therapy Hits Its Stride in the Clinic - Genetic Engineering & Biotechnology News - October 8th, 2022 [October 8th, 2022]
- GWAS, MWAS and mGWAS provide insights into precision agriculture based on genotype-dependent microbial effects in foxtail millet - Nature.com - October 8th, 2022 [October 8th, 2022]
- Making Sense of the Latest Apple-iPhone News - The Motley Fool - October 8th, 2022 [October 8th, 2022]
- Gene therapy brings hope to people with sickle cell, HIV - Monitor - October 8th, 2022 [October 8th, 2022]
- GMO: Everything you need to know about lifting ban - FarmKenya Initiative - The Standard - October 8th, 2022 [October 8th, 2022]
- Century Therapeutics to Present at the SITC 37th Annual Meeting - Yahoo Finance - October 8th, 2022 [October 8th, 2022]
- Cultured meat could help solve the climate crisis. Heres what it will take to move it from the lab to the dinner table - Fortune - October 8th, 2022 [October 8th, 2022]
- Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting -... - October 8th, 2022 [October 8th, 2022]
- Explained: How scientists engineered mosquitoes that will cut the transmission of malaria - Firstpost - October 8th, 2022 [October 8th, 2022]
- Here Are the Biggest Health Industry News Items of 2022 So Far - DocWire News - October 8th, 2022 [October 8th, 2022]